As in the first-line setting in ES-SCLC, a meta-analysis that indirectly compared the efficacy of anti-PD-1 agents plus chemotherapy to anti-PD-L1 agents plus chemotherapy found no significant difference between anti-PD-1 agents and anti-PD-L1 agents [16]. The gene discussed is PDCD1; the disease is small cell lung carcinoma.